LUMBY, B.C., Jan. 20 /PRNewswire-FirstCall/ -- avVaa World Health Care Products Inc. , a global biotechnology company offering therapeutic, natural skin and health care products, announced today industry veteran George Roadman has joined the avVaa team as President and COO, effective immediately. Current President and CEO Jack Farley has agreed to accept a larger role by accepting the role of Chairman and CEO. Farley was instrumental in selecting George for this important role to help avVaa bring their products to market.
avVaa CEO Jack Farley said, “As we continue toward full-scale launch of our Neuroskin skin care lines and secondary pet and equine products, we are excited to add 25-year industry veteran George Roadman to the Company’s management team.”
Farley continued, “With substantial experience in the pharmaceutical sector and particular expertise in product commercialization, George’s experience is a perfect match as we continue to move forward internationally with our popular Neuroskin and pet product lines.”
Roadman has worked in the pharmaceutical industry for more than 25 years and is especially skilled in product management, product positioning, sales and sales management, training, pricing, and strategic planning. Roadman has held progressively more responsible sales and marketing positions at a number of leading healthcare companies, including Abbott Laboratories, AstraZeneca, Baxter Travenol, Bristol Myers Squibb, Eli Lilly and TAP. In these positions, Roadman played a major role in the launch of more than 200 products with sales of several billion dollars, was responsible for creating a brand new division that grew to 200 people and $250 million in sales. In addition, Roadman successfully launched a cardiovascular product that currently has over one billion dollars in sales. Roadman has also led teams that evaluated hundreds of products and reached agreements to buy or sell many of them.
About avVaa World Health Care Products
avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers.
avVaa’s patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin line of skin care products through mass, food and drug channels in the United States and globally. The Company’s secondary line of equine and pet care related products are already being distributed throughout all of Canada. For more information, visit: http://www.avvaa.com or http://www.otcfn.com/avvw .
Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward- looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of avVaa World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
For additional information on avVaa contact Jack Farley CEO / President, at 1-866-772-8822 or visit: http://www.avvaa.com or http://www.otcfn.com/avvw
Investor Relations: Merle Goertz (West Coast) of avVaa World Health Care Products, 1-604-688-2349; or Rick McCaffrey of OTC Financial Network, 1-781-444-6100 ext. 625
avVaa World Health Care Products Inc.
CONTACT: Jack Farley CEO / President, +1-866-772-8822, or Merle Goertz(West Coast), +1-604-688-2349, both of avVaa World Health Care Products; orRick McCaffrey of OTC Financial Network, +1-781-444-6100 ext. 625